CLDN18.2-positive Gastric Adenocarcinoma

Explore clinical trials studying CLDN18.2-positive Gastric Adenocarcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

CLDN18.2-positive Gastric Adenocarcinoma trial results

Completed

NCT01630083

Conditions: CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Gastric Adenocarcinoma
Locations: Site BUL004 Plovdiv, Bulgaria

Site BUL001 Sofia, Bulgaria

Site BUL003 Sofia, Bulgaria

Site BUL005 Sofia, Bulgaria

View all 48 locations

Completed

NCT01671774

Conditions: CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Gastric Adenocarcinoma
Locations: Institut für Klinische Forschung, Krankenhaus Nordwest GmbH Frankfurt am Main, Hesse, Germany

BAG / Onkologische Schwerpunktpraxis Dresden, Saxony, Germany

Charité Universitätsmedizin Berlin - CVK, Med. Klinik m.S. Hämatologie und Onkologie Berlin, Germany

Freiburg University Medical Center, Department of Internal Medicine II, Gastroenterology and Hepatology Freiburg im Breisgau, Germany